Dwight Koeberl

NPI: 1023192184
Total Payments
$8.4M
2024 Payments
$3.4M
Companies
10
Transactions
24
Medicare Patients
11
Medicare Billing
$1,331

Payment Breakdown by Category

Other$8.4M (99.9%)
Travel$7,955 (0.1%)
Food & Beverage$871.58 (0.0%)
Education$10.31 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Acquisitions $8.4M 3 99.8%
Travel and Lodging $7,955 6 0.1%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,000 2 0.1%
Grant $1,000 1 0.0%
Food and Beverage $871.58 8 0.0%
Education $10.31 4 0.0%

Top Paying Companies

Company Total Records Latest Year
Asklepios Biopharmaceutical Inc. $7.4M 2 $0 (2024)
Bayer HealthCare Pharmaceuticals Inc. $1.0M 1 $0 (2022)
GENZYME CORPORATION $13,898 11 $0 (2018)
VERTEX PHARMACEUTICALS INCORPORATED $1,216 2 $0 (2017)
PFIZER INC. $410.21 1 $0 (2017)
Amicus Therapeutics, Inc. $154.75 1 $0 (2021)
Alexion Pharmaceuticals, Inc. $125.00 1 $0 (2018)
Ultragenyx Pharmaceutical Inc. $22.54 1 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2024 $3.4M 1 Asklepios Biopharmaceutical Inc. ($3.4M)
2023 $3.9M 1 Asklepios Biopharmaceutical Inc. ($3.9M)
2022 $1.0M 2 Bayer HealthCare Pharmaceuticals Inc. ($1.0M)
2021 $154.75 1 Amicus Therapeutics, Inc. ($154.75)
2020 $2.49 3 Travere Therapeutics, Inc. ($2.49)
2018 $12,171 8 GENZYME CORPORATION ($12,039)
2017 $3,486 8 GENZYME CORPORATION ($1,860)

All Payment Transactions

24 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
12/30/2024 Asklepios Biopharmaceutical Inc. Acquisitions Cash or cash equivalent $3,431,676.01 General
12/29/2023 Asklepios Biopharmaceutical Inc. Acquisitions Cash or cash equivalent $3,944,327.67 General
12/29/2022 Bayer HealthCare Pharmaceuticals Inc. Acquisitions Cash or cash equivalent $1,005,900.56 General
05/17/2022 Ultragenyx Pharmaceutical Inc. Food and Beverage In-kind items and services $22.54 General
12/06/2021 Amicus Therapeutics, Inc. Food and Beverage In-kind items and services $154.75 General
03/04/2020 Travere Therapeutics, Inc. (820) Cholbam (Drug) Education In-kind items and services $0.83 General
Category: Hepatology
03/04/2020 Travere Therapeutics, Inc. (820) Cholbam (Drug) Education In-kind items and services $0.83 General
Category: Hepatology
03/04/2020 Travere Therapeutics, Inc. (820) Cholbam (Drug) Education In-kind items and services $0.83 General
Category: Hepatology
11/28/2018 Alexion Pharmaceuticals, Inc. Strensiq (Drug) Food and Beverage In-kind items and services $125.00 General
Category: Endocrinology
11/16/2018 GENZYME CORPORATION LUMIZYME (Drug) Travel and Lodging In-kind items and services $5,894.67 General
Category: RARE DISEASE GENETICS
11/16/2018 GENZYME CORPORATION LUMIZYME (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,800.00 General
Category: RARE DISEASE GENETICS
11/16/2018 GENZYME CORPORATION LUMIZYME (Drug) Travel and Lodging In-kind items and services $579.87 General
Category: RARE DISEASE GENETICS
11/16/2018 GENZYME CORPORATION LUMIZYME (Drug) Food and Beverage In-kind items and services $337.35 General
Category: RARE DISEASE GENETICS
11/16/2018 GENZYME CORPORATION LUMIZYME (Drug) Travel and Lodging In-kind items and services $326.07 General
Category: RARE DISEASE GENETICS
09/06/2018 Retrophin, Inc. (820) Cholbam (Drug) Education In-kind items and services $7.82 General
Category: Hepatology
03/12/2018 GENZYME CORPORATION DISEASE STATE (Drug) Food and Beverage In-kind items and services $100.62 General
10/07/2017 GENZYME CORPORATION NO PRODUCT DISCUSSED (Drug) Grant Cash or cash equivalent $1,000.00 General
10/07/2017 GENZYME CORPORATION NO PRODUCT DISCUSSED (Drug) Travel and Lodging Cash or cash equivalent $381.00 General
10/07/2017 GENZYME CORPORATION NO PRODUCT DISCUSSED (Drug) Travel and Lodging Cash or cash equivalent $363.04 General
10/07/2017 GENZYME CORPORATION NO PRODUCT DISCUSSED (Drug) Food and Beverage In-kind items and services $94.87 General
10/06/2017 VERTEX PHARMACEUTICALS INCORPORATED Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,200.00 General
08/11/2017 VERTEX PHARMACEUTICALS INCORPORATED Food and Beverage In-kind items and services $15.67 General
05/09/2017 PFIZER INC. Travel and Lodging In-kind items and services $410.21 General
02/15/2017 GENZYME CORPORATION DISEASE STATE (Drug) Food and Beverage In-kind items and services $20.78 General

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 1 11 14 $4,816 $1,331
Total Patients
11
Total Services
14
Medicare Billing
$1,331
Procedure Codes
1

All Medicare Procedures & Services

1 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2023 11 14 $4,816 $1,331 27.6%

About Dwight Koeberl

Dwight Koeberl is a Pediatrics healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023192184.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dwight Koeberl has received a total of $8.4M in payments from pharmaceutical and medical device companies, with $3.4M received in 2024. These payments were reported across 24 transactions from 10 companies. The most common payment nature is "Acquisitions" ($8.4M).

As a Medicare-enrolled provider, Koeberl has provided services to 11 Medicare beneficiaries, totaling 14 services with total Medicare billing of $1,331. Data is available for 1 year (2023–2023), covering 1 distinct procedure/service records.

Practice Information

  • Specialty Pediatrics
  • Location Durham, NC
  • Active Since 10/25/2006
  • Last Updated 07/10/2023
  • Taxonomy Code 208000000X
  • Entity Type Individual
  • NPI Number 1023192184

Products in Payments

  • LUMIZYME (Drug) $11,938
  • NO PRODUCT DISCUSSED (Drug) $1,839
  • Strensiq (Drug) $125.00
  • DISEASE STATE (Drug) $121.40
  • (820) Cholbam (Drug) $10.31

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatrics Doctors in Durham